Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

ADDvise Group Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

ADDvise Group wird ein jährliches Gewinn- und Umsatzwachstum von 18.3% bzw. 8.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 26.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 19.1% betragen.

Wichtige Informationen

18.3%

Wachstumsrate der Gewinne

26.2%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	24.5%
Wachstumsrate der Einnahmen	8.7%
Zukünftige Eigenkapitalrendite	19.1%
Analystenabdeckung	Low
Zuletzt aktualisiert	22 Apr 2024

Jüngste Aktualisierungen zum künftigen Wachstum

ADDvise Group AB (publ) Just Beat EPS By 69%: Here's What Analysts Think Will Happen Next

Jul 26

Recent updates

ADDvise Group AB (publ)'s (STO:ADDV A) 28% Cheaper Price Remains In Tune With Earnings

Feb 23

Need To Know: Analysts Are Much More Bullish On ADDvise Group AB (publ) (STO:ADDV A) Revenues

Nov 08

ADDvise Group (STO:ADDV A) Ticks All The Boxes When It Comes To Earnings Growth

Oct 21

Does ADDvise Group (STO:ADDV A) Have A Healthy Balance Sheet?

Sep 25

ADDvise Group AB (publ) Just Beat EPS By 69%: Here's What Analysts Think Will Happen Next

Jul 26

News Flash: Analysts Just Made A Meaningful Upgrade To Their ADDvise Group AB (publ) (STO:ADDV A) Forecasts

Mar 15

Is ADDvise Group (STO:ADDV A) A Risky Investment?

Jan 24

Gewinn- und Umsatzwachstumsprognosen

OM:ADDV A - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	2,051	233	272	348	2
12/31/2025	1,920	195	216	290	2
12/31/2024	1,791	162	222	397	2
3/31/2024	1,483	111	86	106	N/A
12/31/2023	1,379	104	157	175	N/A
9/30/2023	1,302	102	208	225	N/A
6/30/2023	1,218	101	189	202	N/A
3/31/2023	1,105	117	211	226	N/A
12/31/2022	959	81	96	110	N/A
9/30/2022	793	55	66	35	N/A
6/30/2022	660	19	34	18	N/A
3/31/2022	545	0	-4	-2	N/A
12/31/2021	469	3	6	10	N/A
9/30/2021	410	7	-32	9	N/A
6/30/2021	380	11	-4	20	N/A
3/31/2021	364	20	42	47	N/A
12/31/2020	359	15	56	57	N/A
9/30/2020	365	17	42	47	N/A
6/30/2020	369	12	33	38	N/A
3/31/2020	360	2	12	17	N/A
12/31/2019	354	4	5	11	N/A
9/30/2019	325	0	-4	0	N/A
6/30/2019	306	-2	1	2	N/A
3/31/2019	280	-1	-3	3	N/A
12/31/2018	271	-1	-5	0	N/A
9/30/2018	260	-7	-19	-13	N/A
6/30/2018	248	-7	-25	-16	N/A
3/31/2018	250	-5	-23	-17	N/A
12/31/2017	244	-6	N/A	-19	N/A
9/30/2017	235	-3	N/A	-19	N/A
6/30/2017	229	1	N/A	-27	N/A
3/31/2017	214	6	N/A	-35	N/A
12/31/2016	198	0	N/A	-32	N/A
9/30/2016	183	-6	N/A	-25	N/A
6/30/2016	173	-13	N/A	-13	N/A
3/31/2016	156	-18	N/A	-15	N/A
12/31/2015	151	-11	N/A	-4	N/A
9/30/2015	160	-8	N/A	-7	N/A
6/30/2015	154	-4	N/A	-6	N/A
3/31/2015	151	-4	N/A	5	N/A
12/31/2014	144	-5	N/A	-9	N/A
9/30/2014	138	-6	N/A	-9	N/A
6/30/2014	137	-4	N/A	4	N/A
3/31/2014	133	-3	N/A	6	N/A
12/31/2013	125	-4	N/A	-6	N/A
9/30/2013	120	0	N/A	9	N/A
6/30/2013	116	-2	N/A	-5	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ADDV ADas prognostizierte Gewinnwachstum (18.3% pro Jahr) liegt über der Sparquote (1%).

Ertrag vs. Markt: ADDV ADie Erträge des Unternehmens (18.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (14.4% pro Jahr).

Hohe Wachstumserträge: ADDV ADie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: ADDV ADie Einnahmen des Unternehmens (8.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (2.1% pro Jahr).

Hohe Wachstumseinnahmen: ADDV ADie Einnahmen des Unternehmens (8.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ADDV ADie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (19.1 %).

ADDvise Group Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 30%

Consensus EPS estimates fall by 19%, revenue upgraded

ADDvise Group AB (publ) Provides Earnings Guidance for the Year 2023

ADDvise Group AB (publ) Just Beat EPS By 69%: Here's What Analysts Think Will Happen Next

Price target increased to kr9.25

Consensus revenue estimates increase by 18%

Recent updates

Addvise Group AB (Publ) Announces Chief Executive Officer Changes

Consensus EPS estimates fall by 30%

First quarter 2024 earnings released: EPS: kr0.22 (vs kr0.20 in 1Q 2023)

ADDvise Group AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 100 million.

Addvise Group AB (Publ) Announces Erland Pontusson Decline Re-Election from the Board

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: kr0.56 (vs kr0.46 in FY 2022)

ADDvise Group AB (publ)'s (STO:ADDV A) 28% Cheaper Price Remains In Tune With Earnings

Investor sentiment deteriorates as stock falls 18%

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 20%

ADDvise Group AB (publ) (OM:ADDV A) acquired Axelerist, Inc. for $29.4 million.

With EPS Growth And More, ADDvise Group (STO:ADDV A) Makes An Interesting Case

Consensus EPS estimates fall by 19%, revenue upgraded

Third quarter 2023 earnings released

ADDvise Group AB (publ) to Report First Half, 2024 Results on Jul 18, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 18%

ADDvise Group AB (publ) (OM : ADDV A) completed the acquisition of Diabetic Supply Inc.

ADDvise Group AB (publ) Announces Management Changes

Addvise Group AB (Publ) Appoints Oliver Humlen as Member of the Executive Management Team

ADDvise Group AB (publ) Provides Earnings Guidance for the Year 2023

New major risk - Financial position

Second quarter 2023 earnings released

Investor sentiment improves as stock rises 19%

ADDvise Group AB (publ) (OM:ADDV A) signed a Letter of Intent to acquire Innovative Endoscopy Components, L.L.C. for $11.75? million.

Here's Why ADDvise Group (STO:ADDV A) Has Caught The Eye Of Investors

Investor sentiment deteriorates as stock falls 26%

Now 32% undervalued

Investor sentiment improves as stock rises 20%

Here's Why ADDvise Group (STO:ADDV A) Can Manage Its Debt Responsibly

ADDvise Group AB (publ) (OM:ADDV A) has signed a Letter of Intent to acquire Kolplast CI S.A. for approximately BRL 210 million.

Investor sentiment improves as stock rises 17%

Is ADDvise Group AB (publ) (STO:ADDV A) Trading At A 43% Discount?

First quarter 2023 earnings released

Investor sentiment improves as stock rises 17%

Full year 2022 earnings released: EPS: kr0.45 (vs kr0.02 in FY 2021)

ADDvise Group AB (publ) (OM:ADDV A) signed a letter of intent to acquire X-Ray Cassette Repair Company, Inc. for approximately $15 million.

Investor sentiment improves as stock rises 18%

Is ADDvise Group (STO:ADDV A) A Risky Investment?

ADDvise Group Appoints Fredrik Mella as Senior Vice President Alongside His Current Role as Chief Operating Officer

High number of new and inexperienced directors

Need To Know: Analysts Are Much More Bullish On ADDvise Group AB (publ) (STO:ADDV A) Revenues

ADDvise Group AB (publ) to Report Fiscal Year 2022 Final Results on Apr 05, 2023

Second quarter 2022 earnings released: EPS: kr0.11 (vs kr0.001 in 2Q 2021)

Investor sentiment improved over the past week

ADDvise Group (STO:ADDV A) Ticks All The Boxes When It Comes To Earnings Growth

ADDvise Group AB (publ), Annual General Meeting, May 05, 2023

Does ADDvise Group (STO:ADDV A) Have A Healthy Balance Sheet?

ADDvise Group AB (publ) (OM:ADDV A) entered into a letter of intent to acquire Clinichain Holding B.V. for €33.80 million.

ADDvise Group AB (publ) Just Beat EPS By 69%: Here's What Analysts Think Will Happen Next

Second quarter 2022 earnings: Revenues exceed analyst expectations

Price target increased to kr9.25

High number of new and inexperienced directors

ADDvise Group AB (publ) (OM:ADDV A) completed the acquisition of Seebreath AB from the shareholders.

ADDvise Group AB (publ) Announces Executive Changes

First quarter 2022 earnings: EPS misses analyst expectations

First quarter 2022 earnings: Revenues in line with analyst expectations

ADDvise Group AB (publ) (OM:ADDV A) completed the acquisition of Surplus Diabetic, Inc for $19.5 million.

News Flash: Analysts Just Made A Meaningful Upgrade To Their ADDvise Group AB (publ) (STO:ADDV A) Forecasts

Consensus revenue estimates increase by 18%

Full year 2021 earnings: EPS misses analyst expectations

Addvise Group AB (Publ) Not to Propose Any Dividend for the Financial Year 2021

Is ADDvise Group (STO:ADDV A) A Risky Investment?

ADDvise Group AB (publ) (OM:ADDV A) signed a Letter of Intent to acquire Surplus Diabetic, Inc. for $19.5 million.

ADDvise Group AB (publ) (OM:ADDV A) signed a Letter of Intent to acquire Zevex Physical Evaluation for $7.3 million.

Chief Financial Officer Aaron Wong has left the company

ADDvise Group AB (publ) (OM:ADDV A) completed the acquisition of Southern Life Systems, Inc.

Third quarter 2021 earnings released